Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 September 2021 | Story Leonie Bolleurs | Photo Supplied
Frans Koning recently obtained a CERA accredited enterprise risk management (ERM) qualification from the Actuarial Society of South Africa.

“If you fail to plan, then you plan to fail.”

“During and after planning, ensure that you identify all risks, since it would be the risks that you did not identify that might sink you.” 

These are two of the beliefs of Frans Koning, Senior Lecturer and Head of the Department of Mathematical Statistics and Actuarial Science at the University of the Free State (UFS), whose outputs in life – whether as lecturer or risk manager – are about planning. 

Koning, a qualified actuary with an interest in corporate governance, has been investing in his growth and development for the past three years by enrolling and obtaining an enterprise risk management (ERM) qualification from the Actuarial Society of South Africa, which is a member of the CERA Global Association (CGA). Having a Chartered Enterprise Risk Actuary (CERA) credential means that he worked through a world-class curriculum that is recognised globally and transferable internationally. This qualification gives professionals greater exposure to the C-suite and leadership, while empowering them to become a more highly valued resource for a company. 

Pulling out all the stops

CGA describes itself as a body that provides accredited risk professionals with strong ERM knowledge to drive better business decisions in finance and insurance. It associates characteristics such as professionalism, ethics and trust, impeccable standards and integrity with students who have obtained the CERA credential. “These professionals can communicate ideas effectively with leadership and is qualified to play varying roles within an organisation, from risk manager to chief risk officer and more,” it states. 

He had to pull out all the stops to obtain this qualification. “This was about 400 hours of study; and absolutely worth it. Since it was very interesting, I did not consider it hard work,” says Koning, who believes in a positive outlook on life. “I have never seen a successful pessimist,” he says. 

This qualification enables him to add extra value in the classroom, teaching Risk Management. Discussing hard questions in class, linking it to practice, i.e., modelling COVID-19 and discussing its effect on life insurance, is what he loves about this profession. He misses student interaction in the classroom, saying that interaction and discussions are not the same with a Blackboard/Teams/Zoom meeting.

A multitude of opportunities 

Koning, who has been with the university since 2003, believes his motivation of students makes a difference in their lives. “Teaching students and seeing them grow into actuaries and chief executive officers of companies gives me great satisfaction,” he states.

He lectures Life Contingencies, which is about calculating life insurance premiums and reserves, as well as Asset and Liability Management, which teaches students about managing the liabilities arising from selling insurance and managing the assets backing these. 

Teaching students and seeing them grow into actuaries and chief executive officers of companies gives me great satisfaction. – Frans Koning

 

As an independent non-executive director (NED) at African Unity Life (Ltd), he also chairs the risk committee and serves as a member of the audit committee. Koning is of the opinion that this qualification will be useful in more board positions than NED. This is but one of his options. According to him, there are a multitude of opportunities in the private sector, as all entities manage risk.

“I also intend to do some research in the space of enterprise risk management, something which I enjoy,” he adds. 

News Archive

Collaboration between UFS and Mayo Clinic to revolutionise cancer treatment
2014-06-27



Attending the lecture were, from the left: Dr Chantel Swart, Prof Lodewyk Kock, Prof Debabrata Mukhopadhyay, Prof James du Preez; back: Prof Pieter van Wyk.
Dr Swart, Profs Kock and Du Preez are from the Department of Microbial, Biochemical and Food Biotechnology. Prof Mukhopadhyay is from the Mayo Clinic (US) and Prof Van Wyk is from the Centre for Microscopy at the UFS.
Photo: Supplied
The UFS made a discovery that may have enormous implications for the treatment of diseases in humans.

Since the discovery, the UFS joined forces with the Mayo Clinic in Rochester, US, in the fight against cancer.

In this collective effort, UFS researchers would be able to assist the Mayo team to:
• see how treatment in cancer patients is progressing,
• target treatments more effectively,
• reduce dosages in order to make treatment gentler on the patient,
• track the effectiveness of the chemotherapy drugs used, and
• gain an accurate view of how the cancer is being eliminated.

Prof Lodewyk Kock, Outstanding Professor at the Department of Microbial, Biochemical and Food Biotechnology, and his team incidentally created a technique to use argon gas particles for the first time on biological material to slice open cells to look inside.

The team that supported Prof Kock includes Dr Chantel Swart, Khumisho Dithebe (PhD student), Prof Hendrik Swart (Department of Physics) and Prof Pieter van Wyk (Centre for Microscopy).

Prof Debabrata Mukhopadhyay from the Mayo Clinic in Rochester, US, got to hear about this breakthrough at the UFS and a collaboration between the two institutions was established.

During a visit to the Bloemfontein Campus, Prof Mukhopadhyay explained novel techniques that make use of gold nanoparticles. These particles attach to chemotherapeutic drugs to selectively target cancer cells – dramatically decreasing the side effects to normal human cells.

For these new drugs (coupled to gold nanoparticles) to be accepted into clinical practice, visual and chemical proof is needed, though. This is where the technique developed by the UFS will play a vital role.

With the technique to look inside cells, the composition, location and metabolism of these drugs can be determined. This will aid in a proof of concept for the application of the nano-drugs. Furthermore, it will enable approval for use of these drugs in clinical trials and eventually could revolutionise cancer treatment as a whole.

For video lectures on the technique used, as well as its findings, follow these links:

1. http://vimeo.com/63643628 (Comic version for school kids)

2. http://vimeo.com/61521401 (Detailed version for fellow scientists)

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept